MiNK Therapeutics, Inc.
149 Fifth Street, Suite 500
New York, NY 10010
November 7, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | MiNK Therapeutics, Inc. |
Registration Statement on Form S-3 (File No. 333-268143)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on November 8, 2022, or as soon as possible thereafter. The Company hereby authorizes Zachary Blume of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please notify Zachary Blume of Ropes & Gray LLP, counsel to the Company, at (617) 951-7663 as soon as the registration statement has been declared effective.
[Signature page follows]
U.S Securities and Exchange Commission
Page 2
| Very truly yours, | ||
| MiNK Therapeutics, Inc. | ||
| By: | /s/ Jennifer S. Buell, Ph.D. | |
| Jennifer S. Buell, Ph.D. President, Chief Executive Officer and Director | ||
[Signature Page to Acceleration Request Letter]